Compare 10X Genomics Inc (TXG) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? 10X Genomics Inc trades at $80 (market cap $9.92B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 32.6× 10X Genomics Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is more actively traded (9,762,021 versus 9,372,166). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| TXG | VEA | |
|---|---|---|
Market Cap | $9.92B | $323.80B |
Volume | 9,372,166 | 9,762,021 |
Sector | Health | — |
52-Week High | $97.74 | $73.79 |
52-Week Low | $11.48 | $58.90 |
Typical Hold Time | 92 Days | 131 Days |
Enterprise Value | $9.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
VEA, the Vanguard FTSE Developed Markets ETF, trades at $70.26, down 1.2% on the day amid a bearish technical signal. The ETF provides cost-efficient exposure to developed markets outside the U.S., with a 0.03% expense ratio and competitive dividend yield. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing stakes while others trimmed positions.
The outlook remains mixed, with technical indicators signaling caution but fundamental strengths in low costs and diversification. Key risks include global market volatility and currency fluctuations. Investors should weigh the ETF's stable, income-oriented profile against near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
